The Cortisol Play With an FDA Approval and an Oncology Kicker

30‑Second Take

Why now? A profitable small-cap biotech that most retail investors can't name just landed one of the biggest FDA approvals in its history. And the commercial launch is ramping

Corcept is a cortisol modulation specialist. Its existing Cushing's drug, Korlym, throws off enough cash to fund the entire pipeline without dilution, which is rare in biotech.

The bigger story is relacorilant, branded Lifyorli, which won FDA approval in late March for platinum-resistant ovarian cancer. That's a genuinely new indication, not a Cushing's replacement, and the addressable market is meaningfully larger than the existing franchise.

CORT stock is trading around $91 and has climbed more than 33% over the last 52 weeks. Still not a household name.

Trade Setup

Time frame: Swing to medium-term (6 to 12 weeks)
Edge type: Launch ramp execution plus pipeline rerating

Snapshot Table

Chart

1-Month Trading Summary: CORT has held around the $91 level for the past four weeks, consolidating after a multi-month run that included the ROSELLA readout in January and the FDA approval in late March.

That's a constructive setup. When a stock consolidates after back-to-back major catalysts, it usually means the momentum chasers have cycled out, leaving a cleaner entry ahead of the launch ramp.

Bull Case 

Core thesis: Corcept built its franchise on Korlym, a cortisol modulator used to treat Cushing's syndrome. That drug alone throws off enough cash to fund the pipeline without dilution.

Most biotechs at this stage are burning cash and issuing shares. Corcept is profitable, growing, and self-funded.

Catalysts: The second leg is Lifyorli. FDA-approved in late March 2026 for platinum-resistant ovarian cancer, this is an entirely separate market from Cushing's.

The ROSELLA Phase 3 trial demonstrated efficacy when relacorilant was combined with nab-paclitaxel in one of the toughest indications in oncology. That readout came in January 2026, and the commercial launch is just now starting to ramp.

Then there's the ongoing Cushing's business. Korlym continues to generate cash, and any future development of relacorilant in Cushing's, where it would offer a cleaner side effect profile than mifepristone, remains optionality that isn't fully priced in.

Add it all up: profitable base business, newly launched oncology drug, pipeline optionality, and a stock that has rerated but still isn't widely followed.

Valuation upside: The addressable market in platinum-resistant ovarian cancer is substantially larger than the Cushing's franchise, meaning even modest launch traction can move the numbers.

Technical tailwind: Consolidation around $91 after the FDA approval suggests the stock is digesting gains rather than rolling over.

Bear Case 

You need to know the risks before you buy.

Launch execution matters. The ROSELLA data is in hand, and the FDA has given the green light. But payer coverage, physician conversion, and manufacturing scale-up all need to click.

Any hiccup in the first two quarters of the Lifyorli launch and the market will punish the stock.

Second, the oncology optionality is now embedded in the price. A stumble in real-world outcomes data or a competitive approval in the same indication could reset expectations fast.

Third, there's a lingering patent and generics overhang on Korlym. Teva has been in litigation for years. Corcept has largely defended the franchise, but one adverse ruling could reset the cash flow assumptions the pipeline depends on.

The setup is asymmetric. Downside if the launch stumbles is bounded by the existing Korlym cash engine, while the upside if Lifyorli commercializes well is a significant multiple on current levels.

Quick Checklist 

✅ Thesis still valid after today's close
✅ Lifyorli launch metrics tracking vs. Analyst expectations
✅ Korlym litigation status and relacorilant label expansion pipeline double-checked

Deep‑Dive Links

• Latest earnings report

• Analyst ratings and price targets

• Short interest data

• Company profile and investor relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha